Shane Neman
Managing Partner @ Neman Ventures
Miami, United States
Shane Neman is a seed investor at Neman Ventures in Miami focused on Health Care and Software. Founder of EZ Texting and JoonBug. Serial entrepreneur and investor in Tech, Real Estate & Hospitality.cA forward-thinking problem solver, consummate optimist and serial entrepreneur, Shane Neman is the prototypical businessman of our modern era. His experience and expertise in business span numerous industries, from technology andtelecommunications to real estate and hospitality. After leaving NYU Medical School early, he started three industry-shifting tech startups (two of them – EZ Texting and JoonBug – acquired) with hundreds of employees and tens of thousands of customers. As an insightful startup backer, Shane’s portfolio includes companies such as Convoy, Prose, Impossible Foods, Universal Standard, Apostrophe, MeetMindful, MapAnything, VinePair and Smylen. Shane is also a prolific real estate developer and investor. From commercial shopping and industrial centers to residential buildings, he owns more than two dozen large-scale properties across the U.S. He holds a degree in Computer Science from New York University, where he received the prestigious Barry M. Goldwater scholarship and was a member of the Phi Beta Kappa academic honor society.
- Total investments:
- 120
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Shane Neman invests in
Stages Shane Neman invests in
Countries Shane Neman invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.5M–$6M
- Series A
- $7M–$120M
- Venture - Series Unknown
- $15M–$115M
Investment Focus
Industry
- Health Care 19 (16%)
- Software 18 (15%)
- Artificial Intelligence 15 (13%)
- Information Technology 9 (8%)
- Biotechnology 8 (7%)
Stage
- Seed 44 (37%)
- Series A 22 (18%)
- Venture - Series Unknown 8 (7%)
- Series B 7 (6%)
- Series C 5 (4%)
Country
- United States 84 (70%)
- Kenya 1 (1%)
- Spain 1 (1%)
- Israel 1 (1%)
- Mexico 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Hark is an AI lab focused on creating advanced personal intelligence through the combination of foundation models and specialized hardware. The company develops an AI interface through custom hardware and autonomous computing, integrated with multimodal models and highly personalized memory. | $700M / Series A / May 20, 2026 | ||
| Scout AI is building the robotic foundation model for defense. | $100M / Series A / Apr 29, 2026 | ||
| Paradromics is building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. | Convertible Note / Dec 20, 2025 | ||
| Nara Organics manufactures organic infant formula delivered directly to the consumers. They offer healthy and nutritional food. The company's products use biodynamic infant formula to complete the nutritional deficit of the baby, enabling parents to take care of their babies' health.The company was founded in 2018 and was based in NewYork. | $15.5M / Venture - Series Unknown / Nov 06, 2025 | ||
| Dyna Robotics is at the forefront of revolutionizing robotic manipulation with cutting-edge foundation models. Our mission is to empower businesses by automating repetitive, stationary tasks with affordable, intelligent robotic arms. Leveraging the latest advancements in foundation models, we're driving the future of general-purposerobotics—one manipulation skill at a time.Dyna Robotics was founded by industry leaders who previously achieved a $350 million exit in grocery deep tech as well as top robotics researchers from DeepMind and Nvidia. Our team blends world-class research, engineering, and product innovation to drive the future of robotic manipulation. With sizable funding already in place, we're positioned to redefine the landscape of robotic automation. Join us to shape the next frontier of AI-driven robotics. | $120M / Series A / Sep 15, 2025 | ||
| Mana.bio develops artificial intelligence–based platforms for drug delivery using lipid nanoparticles (LNPs). The company combines machine learning with nanotechnology to design, test, and refine LNP formulations through computational modeling and laboratory validation. Its technology focuses on extrahepatic tissue targeting and includes researchon lung-targeted delivery and safety improvements through predictive modeling. Mana.bio has introduced ChatLNP, a tool that supports literature analysis, property prediction, and formulation optimization. The platform integrates experimental results with public data to enhance model accuracy and broaden its design capabilities for gene therapy and RNA-based medicines. | Seed / Sep 09, 2025 | ||
| DeepNight is using AI to create the next generation of night vision technology. | Series A / Sep 01, 2025 | ||
| FORT Robotics makes wireless safety systems for dangerous machines. Formerly part of HRI, FORT is a VC-backed company built on more than a decade of experience in safety technology.FORT Robotics is building a first-of-its-kind safety and security platform for smart machines. FORT’s mission is to unlock the full potential of automation byaccelerating development, reducing risk, and building trust in autonomous systems. | $18.9M / Series B / Aug 06, 2025 | ||
| CardiaCare is a medical device for neuromodulation therapy in AFib patients. | Series A / Jul 01, 2025 | ||
| Neuralink develops implantable brain-computer interface (BCI) systems designed to facilitate direct communication between the human brain and external devices. The company focuses on creating a scalable neural implant that records and transmits brain signals with high precision. Neuralink's primary device, often referred to as a"Link," includes ultra-thin threads that are surgically placed in the brain to monitor neural activity and potentially stimulate it. These devices are intended for applications in medical treatment, such as helping individuals with paralysis regain motor function or communication capabilities. Neuralink also invests in developing robotic surgical systems to perform the implantation procedure with high accuracy and minimal invasiveness. The long-term goal involves enabling broader human-computer symbiosis, including interaction with artificial intelligence systems. | $649M / Series E / May 27, 2025 | ||
| See all 120 investments → | |||
Co-Investors
About Neman Ventures
Single Family Office
Neman Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Shane Neman
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Shane Neman invest in?
Shane Neman invests primarily in Health Care, Software and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 120 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Shane Neman's check size?
Shane Neman typically joins rounds of $1.5M–$6M at Seed, $7M–$120M at Series A and $15M–$115M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Shane Neman participates in.
How do I contact Shane Neman?
Public channels for Shane Neman include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Shane Neman last invest?
The most recent investment recorded for Shane Neman closed in May 2026. Shizune tracks 120 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
